PHARVARIS NV (PHVS) 2.43 +0.41 (+20.3%)
2.43 +0.41 (+20.3%)
NL00150005Y4 - Common Stock
Oversold Conditions For Pharvaris (PHVS)
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
ZUG, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium
ZUG, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for...
Pharvaris Becomes Oversold (PHVS)
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
Shares hit their lowest point since November on the FDA's decision in HAE.
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
ZUG, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Notable Two Hundred Day Moving Average Cross - PHVS
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference
ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris Participates in the Kinin 2022 Conference
Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May ...
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment...
Pharvaris to Participate in BofA Securities 2022 Healthcare Conference
ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...